Market Overview

Benzinga's Top #PreMarket Gainers

Related EXEL
Benzinga's Top Upgrades, Downgrades For March 16, 2017
Icahn's (Potential) Move Into Biotech
Old Mutual Asset Managers Uk Ltd Buys Advanced Micro Devices, American International Group, ... (GuruFocus)
Related PGNX
Exclusive: Progenics CEO Talks Regulatory Climate, Positive Trials For Ultra-Orphan Azedra
Watch These 10 Huge Call Purchases In Tuesday Trade
Progenics Pharmaceuticals Sets First Quarter —…–7 Financial Results Call for May 4 (GuruFocus)

Exelixis (NASDAQ: EXEL) shares gained 12.78% to $3.75 in pre-market trading after the company reported that coBRIM has met primary endpoint in phase 3 trial.

Progenics Pharmaceuticals (NASDAQ: PGNX) shares surged 11.08% to $4.71 in pre-market trading. Salix Pharmaceuticals (NASDAQ: SLXP) and Progenics reported that the FDA Office of Drug Evaluation III has approved Salix request for the FDA approval of RELISTOR sNDA.

URS (NYSE: URS) shares jumped 7.92% to $56.14 in pre-market trading after Aecom Technology (NYSE: ACM) announced its plans to buy URS for $4 billion in cash and stock.

Mylan (NASDAQ: MYL) shares gained 3.59% to $52.00 in pre-market trading after the company announced its plans to acquire Abbott's (NYSE: ABT) non-U.S. developed markets specialty and branded generics business in a $5.3 billion all-stock transaction.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers


Related Articles (ABT + ACM)

View Comments and Join the Discussion!